Ramesh Raghupathi graduated from Virginia Commonwealth University with a Ph.D. in Biochemistry and Molecular Biophysics. He did post-doctoral fellowships at the University of Connecticut Health Science Center and the University of Pennsylvania. He served on the faculty in the Department of Neurosurgery at the University of Pennsylvania School of Medicine. He was appointed to the faculty in the Department of Neurobiology and Anatomy at Drexel University College of Medicine in 2003. The ongoing research efforts, funded in part by the National Institutes of Health and the Division of Veteran’s Affairs, are aimed at addressing the feasibility of cellular and pharmacologic strategies to attenuate and reverse TBI pathology. The focus of the research in this group of investigators extend from the basic cell biology of neuronal death and axonal injury to inhibition of seizure induction to the behavioral and rehabilitative strategies (including neuro-robotics and prosthetic use) that may be applied in the chronic post-traumatic phase. The mission of the Raghupathi laboratory is to develop pharmacological treatment and behaviorally therapeutic strategies to respectively, reduce acute post-traumatic neural damage and augment behavioral recovery in the chronic phase. Our research efforts offer some unique capabilities such as comparisons of acute and chronic pharmacologic treatments in multiple models of TBI, in both mice and rats, and, combination treatment strategies that encompass acute pharmacologic treatments with chronic phase behavioral modifications and/or stem cell transplants.